Comparative Visual Outcomes and Complications of Light Adjustable Intraocular Lens Technology: A Scoping Review

Why It Matters

LAL technology delivers finer postoperative refractive control, potentially reducing dependence on glasses and the need for additional corrective surgeries, thereby reshaping cataract‑surgery standards and patient expectations.

Key Takeaways

• LAL lenses lower residual cylinder compared with monofocal IOLs
• Uncorrected visual acuity improves after LAL implantation
• Posterior capsule opacification remains most frequent complication
• Light‑adjustment requires 2–3 week postoperative delay
• UV contamination risk noted in first‑generation LAL models

Pulse Analysis

Cataract surgery has evolved from merely restoring clarity to delivering precise refractive outcomes that rival laser vision correction. Light‑adjustable intraocular lenses (LAL) represent a breakthrough, allowing surgeons to fine‑tune lens power weeks after implantation using controlled ultraviolet light. This post‑operative flexibility addresses residual refractive errors that traditional monofocal lenses cannot correct, positioning LAL as a premium option for patients seeking spectacle‑independent vision and for practices aiming to differentiate their services in a competitive market.

The recent scoping review, covering 20 studies and 1,645 eyes, underscores the clinical advantages of LAL technology. All six head‑to‑head comparisons reported reduced residual cylinder and superior UCVA for LAL eyes, while spherical equivalent results varied. Safety data show that posterior capsule opacification (PCO) remains the most frequent complication, followed by retinal events and secondary surgeries. Notably, the light‑adjustment procedure is typically scheduled 17‑24 days post‑surgery, introducing a logistical delay that may affect patient throughput and satisfaction, particularly for those with prior corneal refractive work.

For ophthalmology practices, adopting LAL lenses entails weighing enhanced visual outcomes against operational challenges. The need for a separate LDD visit extends the care pathway, demanding careful scheduling and patient education. Early‑generation lenses also carry a risk of unintended UV exposure, prompting manufacturers to refine device shielding in newer models. As the technology matures, reduced adjustment timelines and improved safety profiles could accelerate uptake, driving growth in premium IOL markets and influencing reimbursement models that reward superior visual performance.